EGFR and non-small cell lung carcinoma: The JAK‐STAT signalling pathway plays a significant role in the development of different cancers, such as non–small‐cell lung cancer (NSCLC), and impacts how effective EGFR‐TKIs are, as well as the mechanisms by which resistance to these therapies arises.55, 56, 57, 58, 59, 60